CME/CE from MPR


MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for myCME.com. See below for a list of each quarter's courses. Click here to visit MPR's website.




Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits


MPR Drug News


Legionnaire's Outbreak Linked to 31 Cases, 2 Deaths in NYC

The New York City Department of Health and Mental Hygiene is currently investigating an outbreak of Legionnaires' disease that has been linked to 31 reported cases and two deaths to prevent the further spread of Legionella.

Finacea Foam Approved for Rosacea

Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

EDO-S101 NDA Accepted for Relapsed or Refractory Malignancies

The New Drug Application (NDA) for EDO-S101 (Mundipharma) has been accepted by the Food and Drug Administration (FDA) for the treatment of relapsed or refractory hematologic malignancies and solid tumors.

HCTZ Bottles Recalled After Discovery of Blood Thinner Tablet

Unichem Pharmaceuticals issued a voluntary nationwide recall of Hydrochlorothiazide 25mg tablets after the discovery of a Clopidogrel tablet in a bottle.

Study Sheds New Light on Old BP Drug

The diuretic triamterene, which is often used in combination with hydrochlorothiazide (HCTZ) for the treatment of hypertension, appears to enhance the effect of HCTZ in lowering blood pressure (BP) in addition to its potassium-sparing action.